Related Experiment Videos
Clinical application of monoclonal antibodies to small cell lung cancer
Abstract:
Monoclonal antibodies to small cell lung cancer (SCLC) were produced by fusion of P3X63/AgU1 mouse myeloma cells with spleen cells from BALB/c mice immunized against intact cells of SCLC tumors grown in BALB/c athymic nude mice. The antibody TFS-2 demonstrated "pancarcinoma" reactivity showing binding to non-small cell lung cancer (NSCLC) and carcinomas derived from other organs such as stomach, pancreas, and colon. This antibody failed to react with a variety of normal tissues including lung, bone marrow, spleen, stomach, colon, and pancreas. TFS-2 showed complement-mediated cytolysis of target cells. TFS-2 had no significant effects on hematopoietic stem cells. This antibody will serve as a powerful tool for the in vitro removal of tumor cells from bone marrow, thus facilitating high-dose chemotherapy of SCLC with autologous bone marrow transplantation. In contrast, TFS-4 monoclonal antibody reacted specifically with SCLC but not with NSCLS tumors. This antibody can distinguish SCLC from NSCLC tumors in histologic diagnosis at transbronchial biopsy, and in cytological identification of tumor cells in malignant effusion, and in infiltrated bone marrow. Radiolabeled TSF-4 specifically accumulated into SCLC tumors that were implanted subcutaneously into athymic nude mice. Thus, the antibody will be useful not only for diagnosis of lung cancer but also for targeting anti-tumor agents.
Insights
Monoclonal antibodies were developed to target lung cancer. TFS-2 targets various carcinomas, aiding bone marrow transplants, while TFS-4 specifically targets small cell lung cancer (SCLC) for diagnosis and treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are distinct pulmonary malignancies.
- Effective diagnostic and therapeutic tools are crucial for improving patient outcomes in lung cancer.
- Monoclonal antibodies offer targeted approaches for cancer detection and treatment.
Purpose of the Study:
- To develop and characterize novel monoclonal antibodies for targeting small cell lung cancer (SCLC).
- To evaluate the specificity and efficacy of these antibodies in preclinical models.
- To explore their potential applications in cancer diagnosis and therapy.
Main Methods:
- Production of monoclonal antibodies via hybridoma technology, fusing mouse myeloma cells with spleen cells from immunized mice.
- Immunohistochemical analysis to determine antibody reactivity against various cancer cell lines and normal tissues.
- Assessment of complement-mediated cytolysis and in vivo tumor targeting using radiolabeled antibodies in athymic nude mouse models.
Main Results:
- Antibody TFS-2 exhibited broad reactivity against SCLC, NSCLC, and other carcinomas, with no significant binding to normal tissues, and demonstrated complement-mediated cytolysis.
- TFS-2 showed no adverse effects on hematopoietic stem cells, suggesting its utility in purging tumor cells from bone marrow for autologous transplantation.
- Antibody TFS-4 demonstrated high specificity for SCLC, distinguishing it from NSCLC, and showed selective accumulation in SCLC tumors in vivo.
Conclusions:
- Monoclonal antibody TFS-2 is a potential tool for ex vivo tumor cell removal in high-dose chemotherapy for SCLC patients undergoing autologous bone marrow transplantation.
- Monoclonal antibody TFS-4 can aid in the histological and cytological diagnosis of SCLC and serves as a potential vehicle for targeted delivery of anti-cancer agents.